Oral Hydroxychloroquine Plus Oral Sorafenib to Treat Patients With Refractory or Relapsed Solid Tumors
Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
Patients with recurrent, refractory or metastatic solid tumors have a dismal prognosis with
few viable treatment options. Hydroxychloroquine (HCQ) is an agent that has been widely used
to treat malaria. Because HCQ also inhibits autophagy, a process central to survival of
cancer in the face of metabolic stress, including the effects of anti-cancer therapy, it is
now in human cancer trials combined with other agents to attempt to boost the efficacy of
those agents. Autophagy inhibition improves the activity of sorafenib in hepatocellular
carcinoma.
Sorafenib is an oral multi-kinase inhibitor that blocks not only receptor tyrosine kinases
such as KIT, VEGFR and PDGFR but also serine/threonine kinases along the RAS/RAF/MEK/ERK
pathway.
The investigators propose to treat patients with refractory or relapsed solid tumors with
sorafenib, to boost its efficacy while attempting to mitigate its toxicity by combining with
HCQ.
Phase:
Phase 1
Details
Lead Sponsor:
The University of Texas Health Science Center at San Antonio